Pathogenic role of antiprotein-phospholipid antibodies

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 340-357

  Carreras, L O ^a   Forastiero, R R ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Anti b2 glycoprotein I antibodies; Anti pro thrombin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Fetal loss; Lupus anticoagulant; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID PROTEIN ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; FETUS WASTAGE; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; CATTLE; EICOSANOIDS; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; GLYCOPROTEINS; HUMANS; KININOGENS; MICE; MICE, MUTANT STRAINS; PROTEIN C; PROTEIN S; PROTHROMBIN; RABBITS; THROMBOSIS;

EID: 0029949642     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217316     Document Type: Article

References (91)

1. Harris EN: The antiphospholipid syndrome-an introduction; in Harris EN, ExnerT. Hughes Asherson RA (eds): Phospholipid-Binding Antibodies. CRC Press, 1991, pp 373-386.
2. Love PE. Santoro SA: Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorder. Ann Intern Med 1990: 112: 682-698.
3. Conley CL. Hartman RC: A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622.
4. Exner T: Diagnostic methodologies for circulating anticoagulants. Thromb Haemost 1995: 74: 338-344.
5. Harris EN: Antiphospholipid antibodies. Br J Haematol 1990: 74: 1-9.
6. Exner T. Sahman N. Trudinger B: Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun 1988; 155: 1001-1007.
7. Thiagarajan P. Shapiro SS. Dc Marco L: Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest 1980;66:397-405.
8. Rauch J, Tannenbaum H. Janoff AS: Distinguishing plasma lupus anticoagulants from antifactor antibodies using hexagonal (If) phase phospholipids. Thromb Haemost 1989: 62: 892-896.
9. Vermylen J. Arnout J: Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?. J Lab Clin Med 1992; 120: 10-12.
10. McNeil HP. Simpson RJ. Chesterman CN. Krilis SA: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: P2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
11. Galli M. Comfurius P. Maassen C. Hemker HC. De Baets MH. van Breda-Vricsman P.IC. Barbui T, Zwaal RFA. Bevers EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
12. Lee NS. Brewer HB. Osborne JCJ: Beta 2-Glycoprotein I. Molecular properties of an unusual apo lipoprotein, apolipoprotein H. J Biol Chem 1983; 258: 4765-4770.
13. Reid KBM. Day AJ: Structure-function relationships of the complement components. Immunol Today 1989: 10: 177-180.
14. Kandiah DA. Krilis SA: Beta 2-Glycoprotein I. Lupus 1994; 3: 207-212.
15. Hagihara Y, Goto Y. Kato H, Yoshimura T: Structure and function of β-glycopmtein 1: with special reference to the interaction with phospholipid. Lupus 1995: 4: S3-S5.
16. Chonn A. Semple SC. Cullis PR: p2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearcnce of “non-self particles. J Biol Chem 1995: 270: 25845-25849.
17. Hunt J. Krilis S: The fifth domain of p2-glycoprotein-I contains a phospholipid binding site (cys28l-cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994: 152: 653-659.
18. Matsuura E, Igarashi M. Igarashi Y. Katahira T. Nagae H, Ichikawa K, Triplett DA. Koike T: Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on P2-glycopro-tein I structure recognized by anticardiolipin antibodies. Lupus 1995; 4: S13-S17.
19. Kertesz Z, Yu B. Steinkasserer A. Haupt H, Benham A. Sim RB: Characterization of binding of human P2-glycoprotein • to cardiolipin. Biochem J 1995: 310: 315-321.
20. Pierangeli SS. Harris EN, Davis SA, De Lorenzo G: b22-glycoprotcin I (P2-GPI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992;82:565-570.
21. Hunt JE. McNeil HP. Morgan GJ. Crameri RM. Krilis SA: A phospholipid-p2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992: 1: 75-81.
22. Forastiero RR. Martinuzzo ME. Kordich LC. Carreras LO: Reactivity to p2 Glycoprotein 1 clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996; 75: 717-720.
23. Roubey RAS: Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994: 84: 2854-2867.
24. Triplett DA: Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995: 78: 1-31.
25. Viard JP. Amoura Z, Bach JF: Association of anti P2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-186.
26. Arvieux J. Roussel B, Jacob MC, Colomb MG: Measurement of antiphospholipid antibodies by ELISA using p2 glycoprotein I as an antigen. J Immunol Methods 1991: 143: 223-229.
27. Matsuura E. Igarashi Y. Yasuda T. Triplett DA. Koike T: Anticardiolipin antibodies recognize P2 glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994: 179: 457-462.
28. Martinuzzo ME, Forastiero RR. Carreras LO: Anti P2 glycoprotein 1: detection and association with thrombosis. Br J Haematol 1995: 89: 397-402.
29. Pengo V. Biasiolo A, Fior MG: Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when P2-glycoprotein 1 is bound to a suitable surface. Thromb Haemost 1995: 73: 29-34.
30. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB: ‘Anticardiolipin" autoantibodies recognize 02 glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995; 154: 954-960.
31. Galli M. Bevers EM: Inhibition of phospholipid-dependent coagulation reactions by "antiphospholipid antibodies": possible modes of action. Lupus 1994; 3: 223-228.
32. Balestrieri G, Tincani A. Spatola L. Allegri F, Prati E, Cattaneo R. Valesini G. Del Papa N. Meroni P: Anti-beta2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995:4: 122-130.
33. Kandiah DA. Hunt JE. Krilis SA: Epitope mapping studies of antiphospholipid antibodies and 02 GPI using synthetic peptides. Lupus 1995; 4: S7-S11.
34. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA: Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991: 66: 629-632.
35. Galli M, Comfurius P. Barbui T. Zwaal RFA, Bevers EM: Anticoagulant activity of 02-glyco-protein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
36. _glycoProtein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost 1993: 70: 598-602.
37. Cabiedes J. Cabral A, Alarcôn-Segovia D: Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-02-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995: 22: 1899-1906.
38. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A: Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-724.
39. Loeliger A: Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythe matosus?. Thromb Diath Haemorrh 1959; 3: 237-256.
40. Fleck RA, Rapaport SI, Rao LVM: Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519.
41. Oosting JD. Derksen RHWM, Bobbink IWG, Hackeng TM. Bouma BN. de Groot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625.
42. Permpikul P. Rao LVM. Rapaport SI: Functional and binding studies of the roles of prothrombin and 02 glycoprotein I in the expression of lupus anticoagulant activity. Blood" 1994: 83: 2878-2892.
43. Arvieux J. Damige L, Caron C, Reber G, Bensa JC, Colomb MG: Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-1125.
44. Vaarala O. Puurunen M. Mànttâri M. Manninen V. Aho K. Palosuo T: Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-459.
45. Amiral J. Larrivaz I. Cluzeau D. Adam M: Standardization of immunoassays for antiphospholipid antibodies with P2GPI and role of other phospholipid cofactors. Haemostasis 1994; 24; 191-203.
46. Sammaritano LR. Gharavi AE: Antiphospholipid antibodies and placental anticoagulant protein I. Lupus 1994: 3: 263-265.
47. La Rosa L. Meroni PL. Tincani A. Balestrieri G. Faden D. Lojacono A. Morassi L. Brocchi E, Del Papa N, Gharavi A, Sammaritano L. Lockshin M: P2 Glycoprotein I and placental anticoagulant protein 1 in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994; 21: 1684-1693.
48. Rand JH. Wu XX. Guller S. Gil J. Guha A. Scher J. Lockwood CJ: Reduction of annexin-V (placental anticoagulant protein-1) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566-1572.
49. Matsuda J. Saitoh N, Gohchi K. Gotoh M. Tsukamoto M: Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994: 47: 56-58.
50. Sugi T, McIntyre JA: Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995: 86: 3083-3089.
51. Gibson J. Nelson M, Brown R. Salem H. Kronenberg H: Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992: 67: 507-509.
52. Shibata S. Harpel PC. Gharavi A, Rand L, Fillit H: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin Ill-thrombin complexes. Blood 1994: 83: 2532-2540.
53. Carreras LO, Defrcyn G. Machin SJ. Vermylen J. Deman R. Spitz B, Van Assche A: Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981: 1: 244-246.
54. Watson KV. Schorer AE: Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 1991: 90: 47-53.
55. Schorer AE. Duane PG. Woods VL. Niewoehner DE: Some antiphospholipid antibodies inhibit phospholipase A2 activity. J Lab Clin Med 1992: 120: 67-77.
56. Hasselaar P. Derksen RHWM. Blokzijl L. de Groot PG: Thrombosis associated with antiphos pholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost 1988; 59: 80-85.
57. Carreras LO, Maclouf J: The lupus anticoagulant and eicosanoids. Prostaglandins Leukotricnes and Essential Fatty Acids 1993: 49: 483-488.
58. Martinuzzo ME. Maclouf J. Carreras LO. Lévy Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671.
59. Lin YL, Wang CT: Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80; 3135-3143.
60. Shi W. Chong BH. Chesterman CN: Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993: 81: 1255-1262.
61. Arvieux J. Roussel B. Pouzol P. Colomb MG: Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemost 1993; 70: 336-341.
62. Amout J: The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996: 75: 536-541.
63. Shi W. Chong BH, Hogg PJ, Chesterman CN: Anticardiolipin antibodies block the inhibition by b22 glycoprotein 1 of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-345.
64. Lellouche F. Martinuzzo M, Said P. Maclouf J. Carreras LO: Imbalance of thromboxane/prosta-cyclin biosynthesis in patients with lupus anticoagulant. Blood 1991.78: 2894-2889.
65. Habib A. Martinuzzo ME. Carreras LO. Lévy-Toledano S. Maclouf J: Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Thromb Haemost 1995; 74: 770-777.
66. Freyssinet JM. Wiesel ML, Gauchy J. Boneu B, Cazenave JP: An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipids on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost 1986: 55: 309-313.
67. Cariou R, Tobelem G, Bellucci S. Soria J, Soria C. Maclouf J. Caen J: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60: 54-58.
68. Potzch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G: Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995: 125: 56-65.
69. Marciniak E. Romond EH: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432.
70. Bokarewa MI. Bremme K, Falk G, Sten-Linder M. Egberg N, Blomback M: Studies on phospholipid antibodies, APC-rcsistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 78: 193-200.
71. Smirnov MD. Triplett DT. Comp PhC. Esmon NL. Esmon ChT: On the role of phosphatidylctha-nolamine in the inhibition of activated protein C activity by anti phospholipid antibodies. J Clin Invest 1995; 95: 309-316.
72. Mori T. Takeya H. Nishioka J, Gabazza EC. Suzuki K: b22-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Throm Haemost 1996; 75: 49-55.
73. Forasliero RR. Kordich L. Basilotta E. Carreras LO; Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies. Blood Coag Fibrinol 1994; 5; 609-616.
74. Hasselaar P. Derksen RHWM. Oosting JD. Blokzijl L, de Groot PG: Synergistic effect of low-doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 1989; 62: 654-660.
75. Oosting JD. Derksen RHWM. Blokzijl L. Sixma JJ. de Groot PG: Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity-Studies in a thrombosis model. Thromb Haemost 1992; 68: 278-284.
76. Branch DW, Rodgers GM: Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-210.
77. Kornberg A, Blank M, Kaufman S, Shoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-1332.
78. Keeling DM, Campbell SJ. Mackie IJ. Machin SJ, Isenberg DA: The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 1991; 77: 354-359.
79. Tsakiris DA. Marbet GA. Makris PE. Settas L, Ducken F: Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost 1989; 61: 175-177.
80. Violi F. Ferro D. Valesini G, Quintarelli C. Saliola M. Grandilli MA. Balsano F: Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. Br Med J 1990; 300: 1099-1102.
81. Kordich LC, Forastiero RR, Basilotta E, Porterie P, Carreras LO: Natural inhibitors of blood coagulation and Fibrinolysis in patients with lupus anticoagulant. Blood Coag Fibrinol 1992; 3: 765-771.
82. Mackworth-Young CG, Andreotti F. Harmer I. Loizou S. Pöttinger BE. Pearson JD. Davies GJ. Maseri A, Walport MJ: Endothelium-derived haemostatic factors and the antiphospholipid syndrome. Br J Rheumatol 1995; 34: 201-206.
83. Del Papa N. Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G. Meroni PL: Relationship between anti-phospholipid and anti-endothelial cell antibodies: ß2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13: 179-185.
84. Le Tonquèze M. Salozhin K. Dueymes M, Piette JC, Kovalev V, Shoenfeld Y. Nassonov E, Youinou P: Role of ß2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 1995:4: 179-186.
85. Gharavi AE: Anti-phospholipid syndrome in murine lupus; in Harris EN, ExnerT, Hughes GRV. Asherson RA (eds): Phospholipid-Binding Antibodies. CRC Press, 1991, pp 403-416.
86. Hashimoto Y. Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T: Anlicardiolipin antibodies in (NZW x BXSB) FI mice: a model of antiphospholipid syndrome. J Immunol 1992: 149: 1063-1068.
87. Branch DW. Dudley DJ, Mitchell MD. Creightari KA, Abott JM, Hammond EH. Daynes RA: Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990: 163: 210-216.
88. Blank M, Cohen J, Toder V, Shoenfeld Y: Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sei USA 1991: 88: 3069-3073.
89. Bakimcr R, Fishman P. Blank M, Srednc B. Djaidetti M. Shoenfeld Y: Induction of primary anti phospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992: 89: 1558-1563.
90. Gharavi AE, Sammaritano LR. Bovastro JL, Wilson WA: Specificities and characteristics of b22 glycoprotein I-induced antiphospholipid antibodies. J Lab Clin Med 1995; 125: 775-778.
91. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN: Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 71: 670-674.